A clinical-stage biopharmaceutical firm developing novel therapies for severe inflammatory diseases with significant R&D investments but no current commercial revenue.
Investors might consider this stock if they believe in the transformative potential of the company's proprietary platform to cure severe inflammatory diseases that lack current treatments. The company has secured sufficient cash reserves to fund operations for a significant period, providing runway to advance multiple candidates into clinical trials without immediate revenue pressure.
The absence of commercial revenue and a substantial accumulated deficit of $414.6M indicate a high-risk profile dependent on successful drug approvals and continuous capital raising. The widening net loss from $-53.8M in 2022 to $-70.5M in 2024 suggests escalating burn rates that could strain liquidity if external funding becomes unavailable.
Werewolf Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates for severe inflammatory diseases, leveraging its proprietary platform to address unmet medical needs. While the company currently has no commercial revenue, it operates primarily in the United States with strategic collaborations aimed at advancing its pipeline toward late-stage clinical trials and potential regulatory approval.
The company reported a net loss of $70.5M in the latest period, driven primarily by elevated research and development expenses of $56.4M and general and administrative costs of $19.0M. Despite these losses, cash flow from operations was partially offset by interest income of $6.7M and financing activities provided $13.1M, resulting in a net decrease in cash of $43.4M while maintaining over $111M in cash equivalents.
The biopharmaceutical industry is characterized by high capital expenditure, long development cycles, and significant regulatory hurdles before products reach the market. Companies in this sector often rely on strategic partnerships to share risk and accelerate the path to commercialization while competing with large established players and emerging biotechs.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $-16.4M | $-19.9M | $-1.9M |
| Gross Profit | $16.4M | $19.9M | $1.9M |
| Operating Expenses | $72.5M | $60.4M | $75.5M |
| Operating Income | $-56.1M | $-40.5M | $-73.6M |
| R&D | $53.8M | $41.8M | $56.4M |
| G&A | $18.7M | $18.7M | $19.0M |
| Stock-Based Comp | $7.4M | $8.0M | $8.8M |
| Depreciation | $1.1M | $1.8M | $1.8M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | — | $3.1M | — |
| Interest Income | — | $7.4M | $6.7M |
| Pre-Tax Income | $-56.1M | $-40.5M | $-73.6M |
| Income Tax | $-2.2M | $-3.1M | $-3.1M |
| Continuing Ops | $-53.8M | $-37.4M | $-70.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-53.8M | $-37.4M | $-70.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-53.8M | $-37.4M | $-70.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $140.2M | $138.4M | $113.1M |
| Cash & Equivalents | $129.3M | $134.3M | $111.0M |
| Prepaid Expenses | $4.0M | $2.7M | $2.1M |
| Other Current Assets | $6.9M | $1.4M | $0 |
| Long-Term Assets | $20.0M | $36.5M | $13.9M |
| PP&E (Net) | $9.0M | $8.0M | $6.3M |
| Operating Leases | $8.5M | $6.9M | $6.0M |
| Other LT Assets | $2.6M | $21.6M | $1.5M |
| Total Assets | $160.2M | $174.8M | $126.9M |
| Current Liabilities | $24.0M | $19.4M | $15.2M |
| Accounts Payable | $1.2M | $1.3M | $3.0M |
| Current Leases | $2.1M | $1.6M | $1.6M |
| Deferred Revenue | $6.5M | $907.0K | $0 |
| Other Current Liab | $0 | $6.7M | $0 |
| Long-Term Liabilities | $13.9M | $44.1M | $38.4M |
| LT Operating Leases | $12.6M | $11.0M | $9.4M |
| Other LT Liab | $191.0K | $32.7M | $28.9M |
| Total Liabilities | $37.9M | $63.5M | $53.5M |
| Shareholders' Equity | $122.3M | $111.4M | $73.4M |
| Paid-In Capital | $429.0M | $455.4M | $488.0M |
| Retained Earnings | $-306.7M | $-344.1M | $-414.6M |
| Total L&E | $160.2M | $174.8M | $126.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-53.8M | $-37.4M | $-70.5M |
| Non-Cash Adjustments | $-4.7M | $24.3M | $15.8M |
| Working Capital Changes | $17.9M | $-19.6M | $-1.5M |
| Cash from Operations | $-40.6M | $-32.6M | $-56.2M |
| Capital Expenditures | $3.6M | $769.0K | $254.0K |
| Cash from Investing | $-3.6M | $-769.0K | $-254.0K |
| Cash from Financing | $15.9M | $58.4M | $13.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-28.3M | $25.0M | $-43.4M |
| Beginning Cash | $158.8M | $130.5M | $155.6M |
| Ending Cash | $130.5M | $155.6M | $112.2M |
The company's operations are centered on its drug discovery and development platform, which includes the conduct of research and development activities, management of clinical trial costs, and strategic licensing or collaboration agreements to advance therapeutic candidates in the inflammatory disease space.
1. Lack of current revenue streams relies entirely on successful progression of clinical candidates and external funding sources like equity issuances or grants. 2. High burn rate driven by substantial R&D expenses ($56.4M in the latest period) could lead to cash depletion if financing is not secured. 3. Clinical trial failures or regulatory setbacks for pipeline assets would significantly impact future valuation and operational continuity. 4. Dilution risk from equity issuances, evidenced by recent common share issuances of $23.6M, which may increase existing shareholder dilution.
1. Proprietary molecular biology technology platform enabling efficient identification and optimization of novel therapeutic targets for severe inflammatory conditions. 2. Strategic external collaborations that provide funding and de-risk development stages without requiring immediate commercial sales. 3. Experienced management team with a track record in navigating the biopharmaceutical development lifecycle from discovery to potential market launch.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.